With new $106M crossover round, Tenaya preps heart failure programs for the clinic — and maybe an IPO
Less than a year and a half since pulling in its last round of funding, Tenaya Therapeutics is back with a crossover round that could set it up for an IPO down the road.
Private and public investors have now jumped aboard the Tenaya train to the tune of a $106 million Series C, the company announced Monday morning, with the hopes of advancing its lead gene therapy program for heart failure into the clinic. Tenaya also aims to fund its other heart failure platforms, having made much progress in cellular regeneration and precision medicine as well, CEO Faraz Ali told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.